A phase I study to determine the safety and effect of soluble beta-glucan (SBG) in combination with rituximab and COP/CHOP in patients with non-Hodgkin's lymphoma.

Trial Profile

A phase I study to determine the safety and effect of soluble beta-glucan (SBG) in combination with rituximab and COP/CHOP in patients with non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2009

At a glance

  • Drugs Soluble beta 1,3-1,6 glucan (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Status changed from recruiting to active, no longer recruiting, according to a Biotec Pharmacon media release.
    • 06 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top